Takeda Pharmaceuticals Inc. (NYSE:TAK) is one of them Most pledge deposits under $20. On March 2, Takeda and Protagonist Therapeutics announced that the US FDA had accepted the new drug application and granted priority review for Rosfertide. This investigational, first-in-class hepcidin mimetic is aimed at treating polycythemia vera/PV in adults, a rare blood cancer characterized by a dangerous overproduction of red blood cells.
Given its ability to address significant unmet needs, the FDA has set the prescription drug user fee rule’s implementation date for Q3 2026. The regulatory submission is supported by data from a Phase 3 validation study, along with long-term results from the Phase 2 REVIVE and THRIVE trials. Clinical findings have shown that rosafertide, when added to the standard of care, doubles the response rate compared to standard therapy alone. Key benefits include sustained control of hematocrit levels below 45%, a significant reduction in the need for painful phlebotomy procedures, and improvement in patient-reported symptoms such as fatigue.
Under the 2024 collaboration agreement, Takeda manages the regulatory strategy and future global filings, while Protagonist retains the option to co-commercialize the drug in the United States through a profit-sharing structure. Rusfertide works by mimicking the hormone hepcidin to regulate iron homeostasis, effectively targeting the underlying mechanism of the disease. If approved, it would provide a subcutaneous treatment option for patients who currently struggle to manage blood clots and are at risk of life-threatening thrombotic events such as stroke or embolism.
Copyright: bbtreesubmission / 123RF Stock Image
Takeda Pharmaceutical Co., Ltd. (NYSE:TAK) researches, develops, manufactures, markets, and out-licenses pharmaceutical products in Japan and internationally. It offers pharmaceutical products for gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience.
While we acknowledge TAK’s potential as an investment, we believe some AI stocks offer more potential and lower risk. If you’re looking for the most undervalued AI stocks that stand to benefit significantly from Trump-era tariffs and the offshore trend, check out our free report Best short-term AI stocks.
Read more: 40 most popular stocks among hedge funds heading into 2026 and 33 stocks that should double in 3 years.
Disclosure: None. Follow the inside port on Google News.
